化合物C25-140 T7889

Product Introduction
Bioactivity


英文名: C25-140

描述: C25-140 是一种具有口服活性和一定选择性的 TRAF6-Ubc13相互作用抑制剂。它直接与 TRAF6 结合，阻断 TRAF6 和 Ubc13 的相互作用，降低 TRAF6 和 NF-κB 的活性，并与自身免疫对抗。

细胞实验: Cell Line:TRAF6WT . Concentration:10 μM, 20 μM, 30 μM . Incubation Time:2 hours

体外活性: C25-140 dose-dependently impedes TRAF6-Ubc13 interaction.It?(10-30 μM;?2 hours) effectively reduces TRAF6-mediated ubiquitin chain formation.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 62.5 mg/mL (136.59 mM)


关键字: Ubiquitin conjugating enzyme | Ubiquitin ligase | Ubiquitin activating enzyme | C25-140 | C25 140 | TNF Receptor | E3 ligating enzyme | C-25-140 | E1/E2/E3 Enzyme | C25140 | Tumor Necrosis Factor Receptor | E2 conjugating enzyme | E1 activating enzyme | TNFR | inhibit | Inhibitor

相关产品: Adalimumab | Taxiresinol | β-Anhydroicaritin | Fisetin | Varlilumab | Selinidin | Moracin D | Neoechinulin A | Ilexgenin A | Macluraxanthone

相关库: HIF-1 Signaling Pathway Compound Library | Anti-Breast Cancer Compound Library | Pyroptosis Compound Library | Transcription Factor-Targeted Compound Library | Immuno-Oncology Compound Library | Anti-Lung Cancer Compound Library | Inhibitor Library | PPI Inhibitor Library | NO PAINS Compound Library | Bioactive Compound Library

化合物C25-140 T7889信息由TargetMol中国为您提供，如您想了解更多关于化合物C25-140 T7889报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途